Cache Advisors LLC Acquires New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Cache Advisors LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 10,909 shares of the biopharmaceutical company's stock, valued at approximately $1,008,000.

A number of other large investors have also made changes to their positions in the stock. FMR LLC increased its holdings in shares of Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares in the last quarter. Wellington Management Group LLP grew its stake in Gilead Sciences by 3.1% in the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after acquiring an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC grew its stake in Gilead Sciences by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after acquiring an additional 749,047 shares during the last quarter. Norges Bank acquired a new stake in Gilead Sciences in the 4th quarter valued at about $1,789,254,000. Finally, Northern Trust Corp grew its stake in Gilead Sciences by 19.7% in the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after acquiring an additional 2,458,954 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the transaction, the chief financial officer now owns 169,061 shares of the company's stock, valued at approximately $19,977,938.37. The trade was a 9.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider now directly owns 121,152 shares of the company's stock, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,929 shares of company stock valued at $5,644,780 over the last 90 days. 0.27% of the stock is owned by company insiders.

Gilead Sciences Stock Up 1.6%

Shares of GILD stock traded up $1.72 during mid-day trading on Tuesday, reaching $109.09. 7,928,580 shares of the company were exchanged, compared to its average volume of 7,726,852. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market capitalization of $135.70 billion, a P/E ratio of 294.84, a P/E/G ratio of 0.71 and a beta of 0.26. The business's 50 day simple moving average is $105.27 and its 200 day simple moving average is $100.46.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business's quarterly revenue was down .3% compared to the same quarter last year. During the same quarter last year, the company earned ($1.32) earnings per share. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.90%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio is presently 66.53%.

Analysts Set New Price Targets

Several research firms have issued reports on GILD. Morgan Stanley raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Royal Bank of Canada raised their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. Piper Sandler raised their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Oppenheimer decreased their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Finally, JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.